Publications by authors named "Wenwang Lang"

Claim this Profile
C
Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China.
Wenwang Lang, Liuyong Mei, Qiang Xiao, Zujin Zhou, Huiqing Jiang

Front Immunol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
Ming Ouyang, Jiangbo Wang, Gaofeng Zhang, Bei Huang, Lin Deng, Wenwang Lang

Front Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China.
Wenwang Lang, Jiangbo Wang, Ming Ouyang, Haiqing Zhao, Tingting Zhou

PLoS One· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.
Wenwang Lang, Jiangbo Wang, Haiqing Zhao, Yulong He, Qinling Jiang

Clin Transl Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring resistance to initial chemotherapy in small cell lung cancer: The role of bone metastasis and other clinicopathologic characteristics.
Yulong He, Xiaorong Tang, Fang Yang, Qinling Jiang, Lin Deng, Wenwang Lang

Medicine (Baltimore)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system.
Wenwang Lang, Yulong He, Changchun Hou, Hua Li, Qinling Jiang

Front Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
Wenwang Lang, Qi Ai, Yulong He, Yufei Pan, Qinling Jiang

Int J Clin Pharm· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China.
Wenwang Lang, Qi Ai, Wenwen Zhang, Qinling Jiang, Yulong He

Front Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system.
Wenwang Lang, Lian Deng, Meijun Lu, Ming Ouyang

Expert Rev Pharmacoecon Outcomes Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
Wenwang Lang, Lian Deng, Bei Huang, Dongmei Zhong, Gaofeng Zhang

Clin Drug Investig· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.
Wenwang Lang, Jiarong Wei, Qinling Jiang, Qi Ai, Xianling Zhao

Int J Clin Pharm· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis